Edition:
United Kingdom

Ocular Therapeutix Inc (OCUL.OQ)

OCUL.OQ on NASDAQ Stock Exchange Global Market

6.38USD
9:00pm BST
Change (% chg)

$-0.07 (-1.09%)
Prev Close
$6.45
Open
$6.44
Day's High
$6.51
Day's Low
$6.29
Volume
49,248
Avg. Vol
123,678
52-wk High
$11.79
52-wk Low
$3.30

Chart for

About

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $240.44
Shares Outstanding(Mil.): 37.28
Dividend: --
Yield (%): --

Financials

  OCUL.OQ Industry Sector
P/E (TTM): -- 35.59 33.60
EPS (TTM): -2.20 -- --
ROI: -116.69 14.13 13.19
ROE: -162.21 16.91 15.00

BRIEF-Ocular Therapeutix Reports Q4 Loss Per Share $0.44

* OCULAR THERAPEUTIX™ REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND BUSINESS UPDATE

08 Mar 2018

BRIEF-Summer Road Reports 8.4 Pct Passive Stake In Ocular Therapeutix

* SUMMER ROAD LLC REPORTS 8.4 PERCENT PASSIVE STAKE IN OCULAR THERAPEUTIX INC AS OF JANUARY 29, 2018 - SEC FILING‍​ Source text: (http://bit.ly/2BjW1c4) Further company coverage:

08 Feb 2018

BRIEF-Ocular TherapeutixTM Announces Public Offering Of 6.50 Mln Common Shares

* OCULAR THERAPEUTIXTM ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

25 Jan 2018

BRIEF-Ocular Therapeutix Announces Proposed Public Offering Of Common Stock

* OCULAR THERAPEUTIX™ ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

24 Jan 2018

BRIEF-Ocular Therapeutix Announces Kevin Hanley As Senior Vice President Technical Operations

* OCULAR THERAPEUTIX ANNOUNCES KEVIN HANLEY AS SENIOR VICE PRESIDENT, TECHNICAL OPERATIONS AND NAYMISHA PATEL AS VICE PRESIDENT OF QUALITY Source text for Eikon: Further company coverage:

08 Jan 2018

Ocular Therapeutix gets subpoena from SEC over eye pain drug

Ocular Therapeutix Inc said on Friday the U.S. Securities and Exchange Commission (SEC) had issued a subpoena seeking information about the company's eye-pain drug Dextenza.

22 Dec 2017

BRIEF-Ocular Therapeutix Provides Legal Update

* OCULAR THERAPEUTIX INC - ON DEC. 21, CO WAS SERVED WITH A NEW DERIVATIVE COMPLAINT

22 Dec 2017

Ocular Therapeutix gets subpoena from SEC over eye pain drug

Dec 22 Ocular Therapeutix Inc said on Friday the U.S. Securities and Exchange Commission (SEC) had issued a subpoena seeking information about the company's eye-pain drug Dextenza.

22 Dec 2017

BRIEF-Ocular Therapeutix posts Q3 loss per share $0.54

* Ocular Therapeutix reports third quarter 2017 financial results and provides corporate update

07 Nov 2017

Earnings vs. Estimates